title: Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets.
abstract: The neuropeptide melanocyte-inhibiting factor (MIF) or L-propyl-L-leucyl-glycinamide (PLG) has been reported in some studies to improve the motor signs of Parkinson's disease (PD) and in rodent models of PD. In this study of oral and intravenous MIF in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmosets, a wide range of doses of MIF administered alone (0.25, 1, 2, 5, 10, 20 mg/kg orally) did not increase locomotor activity, relieve motor disability, or induce dyskinesias. When MIF (1.0 and 5.0 mg/kg orally or 10 and 20 mg/kg intravenously) was administered concomitantly with levodopa/benserazide, no significant differences in motor function or dyskinesias were observed compared with levodopa/benserazide alone. The results of this first study of MIF in the marmoset MPTP model provide no encouragement for the reinvestigation of MIF in the clinical management of the motor signs of PD.
authors: Reta Lila Weston Institute of Neurological Studies, University College London, UK.
authors: Regina
authors: R
authors: Katzenschlager
authors: Michael J
authors: MJ
authors: Jackson
authors: Sarah
authors: S
authors: Rose
authors: Kim
authors: K
authors: Stockwell
authors: Kayhan A
authors: KA
authors: Tayarani-Binazir
authors: Mohammed
authors: M
authors: Zubair
authors: Lance A
authors: LA
authors: Smith
authors: Peter
authors: P
authors: Jenner
authors: Andrew J
authors: AJ
authors: Lees
mesh_terms: D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000284:Administration, Oral; D000818:Animals; D000978:Antiparkinson Agents / Q000008:administration & dosage* / Q000633:toxicity; D001545:Benserazide / Q000008:administration & dosage / Q000633:toxicity; D002144:Callithrix; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D007262:Infusions, Intravenous; D007980:Levodopa / Q000008:administration & dosage / Q000633:toxicity; D008124:Locomotion / Q000187:drug effects; D009075:MSH Release-Inhibiting Hormone / Q000008:administration & dosage* / Q000633:toxicity; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D020734:Parkinsonian Disorders / Q000188:drug therapy*
chemical_list: D000978:Antiparkinson Agents; D007980:Levodopa; D001545:Benserazide; D009075:MSH Release-Inhibiting Hormone; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine